



2641
#3
EN
3-6-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: K.W. Miller et al.

Attorney Docket No.: TELT118399

Application No.: 10/090,134

Group Art Unit: 2641

Filed: February 28, 2002

Title: SELECTION OF VOICE CONNECTION TYPE

RECEIVED
FEB 26 2003
Technology Center 2600

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Seattle, Washington 98101

February 20, 2003

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
2. _____ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. _____, filed _____. The references listed on the attached form were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application.
3. X A concise explanation of the relevance of document Cite No. F1 (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided in an English abstract appended to said document.
4. _____ This Information Disclosure Statement is being filed concurrently with the above-identified application.
5. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first




LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESSSM
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

6. _____ The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,


CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}


Gary S. Kindness
Registration No. 22,178
Direct Dial No. 206.695.1702

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on the below date.

Date:

2/21/03



GSK:ejh/nfs

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



**SUPPLEMENTAL INFORMATION CITED BY APPLICANT(S) THAT MAY BE
MATERIAL TO THE PROSECUTION OF THE SUBJECT APPLICATION**

Applicants: K.W. Miller et al. Attorney Docket No. TELT118399
Application No.: 10/090,134 Group Art Unit: 2641
Filed: February 28, 2002
Title: SELECTION OF VOICE CONNECTION TYPE

RECEIVED
FEB 26 2003
Technology Center 2029

U.S. PATENT DOCUMENTS

*Examiner Cite	Kind	Date	
Initials No. Document No.	Code	(mm/dd/yyyy)	Name
NONE			

FOREIGN PATENT DOCUMENTS

*Examiner Cite	Kind	Publication Date	Country	English Abstract Provided	Translation Provided
Initial No. Document No.	Code	(mm/dd/yyyy)			
_____ F1	DE 196 45 368	A1	04/16/1998	Germany	X
_____ F2	EP 0 907 280	A2	04/07/1999	EPC	X X
_____ F3	WO 00/72536	A1	11/30/2000	PCT	X X
_____ F4	EP 1 071 246	A2	01/24/2001	EPC	X X
_____ F5	2001-53794		02/23/2001	Japan	X

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Cite
Initial No.

NONE

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GSK:ejh/nfs